The purpose of this research was to study whether the bioavailability of ramipril could be improved by administering lovastatin solid lipid nanoparticles (SLN) duodenally to rats. Ramipril SLN were developed using triglycerides by solvent emulsification followed by ultrasonication. Particle size and zeta potential were measured by photon correlation spectroscopy. The solid state of the drug in the SLN and lipid modification was characterized. Bioavailability studies were conducted in male Wistar rats after intraduodenal administration of ramipril suspension and SLN. Stable ramipril SLN having a mean avg size 47.77 nm and a zeta potential range of –16 to –21 mV were developed. About 42% was entrapped in the SLN. Ramipril was dispersed in an amorphous state and triglycerides were in β1 form in the SLN. In vitro stability studies showed the slow release and stability of ramipril SLN. The relative bioavailability of ramipril SLN was increased by 2.5 times compared with the reference ramipril suspension.
Loading....